Adding Abiraterone to Prednisone Significantly Prolongs Time to Pain Progression in Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer

Get Permission

Ethan Basch, MD

An interim analysis of the COU-AA-302 phase III trial in asymptomatic or mildly symptomatic chemotherapy-naive men with metastatic castration-resistant prostate cancer showed that the addition of abiraterone (Zytiga) to prednisone significantly delayed radiographic progression and improved overall survival although the prespecified significance level of P ≤ .0008 was not reached.1 On this interim analysis, the addition of abiraterone also significantly delayed time to opiate use for cancer-related pain, patient-reported pain intensity progression, and health-related quality-of-life deterioration.

In a recently reported analysis in The Lancet Oncology, Ethan Basch, MD, of The University of North Carolina at Chapel Hill, and colleagues described patient-reported outcomes in the second preplanned interim analysis of the trial. The analysis showed that the addition of abiraterone delayed patient-reported pain progression and health-related quality-of-life deterioration compared with prednisone alone.

Study Details

In the multinational, double-blind trial, 1,088 patients with progressive, metastatic castration-resistant prostate cancer were randomly assigned to receive abiraterone at 1 g/d plus prednisone (5 mg twice daily; n = 546) or prednisone plus placebo (n = 542) in continuous 4-week cycles. Eligible patients were asymptomatic (score of 0 or 1 on item three of the Brief Pain Inventory Short Form [BPI-SF] questionnaire) or mildly symptomatic (score of 2 or 3) and had not previously received chemotherapy.

Pain was assessed with the BPI-SF questionnaire, and health-related quality of life was assessed with the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire.  Predefined thresholds for pain progression and deterioration in functional status were: increases of ≥ 30% from baseline for the progression of mean pain intensity and progression of worst pain intensity items and an increase of ≥ 50% of baseline standard deviation for the progression of interference of pain with activities of daily living item on the BPI-SF; and decreases of 10, 9, 9, 3, and 3 points from baseline for the total score, general function score (physical well-being, social and family well-being, emotional well-being, and functional well-being subscales), trial outcome index, prostate cancer–specific subscale, and general function subscales, respectively, on FACT-P. No adjustments for multiple comparisons were made because of the exploratory nature of these analyses.

At baseline the abiraterone/prednisone and prednisone groups had similar FACT-P and subscale scores, 69% vs 65% were asymptomatic and 24% vs 28% were mildly symptomatic, and 65% vs 69% were using no analgesics and 32% vs 26% were using nonopiate analgesics. In both groups, cumulative compliance for completion of both the BPI-SF and FACT-P was ≥ 95% for all treatment cycles.

Pain Progression

At the time of the second prespecified interim analysis, median follow-up was 22.2 months (interquartile range, 20.2–24.8 months). The abiraterone/prednisone group had significantly prolonged median time to progression of mean pain intensity (26.7 vs 18.4 months, hazard ratio [HR] = 0.82, P = .0490) and median time to progression of pain interference with daily activities (10.3 vs 7.4 months, HR = 0.79, P = .005). The abiraterone/prednisone group had a nonsignificantly increased median time to progression of worst pain intensity (26.7 vs 19.4 months, HR = 0.85, P = .109.

In a post hoc sensitivity analysis in which progression was defined as change in BPI-SF worst pain intensity by two points from baseline, median time to progression was not reached in either group; median time to progression at the 25th percentile was significantly longer with abiraterone/prednisone (14.8 vs 12.0 months, HR = 0.78, P = .045).

Health-Related Quality-of-Life Deterioration

On FACT-P assessment, abiraterone/prednisone was associated with significantly prolonged median time to health-related quality-of-life deterioration on FACT-P total score (12.7 vs 8.3 months, HR = 0.78, P = .0028), prostate cancer–specific subscale (11.1 vs 5.8 months, HR = 0.70, P < .0001), trial outcome index (13.9 vs 9.3 months, HR = 0.75, P = .0006), general function score (16.6 vs 11.1 months, HR = 0.76, P = .0023), emotional well-being subscale (22.1 vs 14.2 months, HR = 0.71, P = .0008), and functional well-being subscale (13.3 vs 8.4 months, HR = 0.76, P = .0012), with no difference between groups being observed only for the social and family well-being subscale (18.4 vs 16.6 months, HR = 0.94, P = .5283).

The investigators concluded: “Abiraterone plus prednisone delays patient-reported pain progression and [health-related quality-of-life] deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. These results provide further support for the efficacy of abiraterone in this population.” ■

Disclosure: The study was funded by Janssen Research & Development. For full disclosures of the study authors, visit


1. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013.

2. Basch E, Autio K, Ryan CJ, et al: Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 14:1193-1199, 2013.

Related Articles

COMMENTARY: Correctly Assessing Pain Progression and Quality-of-Life Deterioration in Metastatic Castration-Resistant Prostate Cancer

The therapeutic landscape for the treatment of castration-resistant prostate cancer has changed dramatically in the past 4 years, as five new agents affecting different aspects of the malignant process were proven to prolong life. The results are a great benefit to patients, but at the same time...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.